Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27138422 | 1.00 | EGFR (0.52) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL27152038 | 1.00 | EGFR (0.52) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL27140098 | 1.00 | EGFR (0.52) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL24714697 | 1.00 | EGFR (0.52) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL27136436 | 0.88 | EGFR (0.61) | EGFRERBB2SRCERBB4 | |
| SCHEMBL27136435 | 0.88 | EGFR (0.61) | EGFRERBB2SRCERBB4 | |
| SCHEMBL24714732 | 0.88 | EGFR (0.43) | EGFRERBB2KDRFGFR1FLT1 | |
| SCHEMBL30979940 | 0.86 | EGFR (0.57) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL30820496 | 0.86 | EGFR (0.57) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL27136426 | 0.86 | EGFR (0.57) | EGFRERBB2ABL1PDGFRBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885ABL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.